Literature DB >> 7870220

Prognostic factors in bilateral breast cancer.

K Engin1.   

Abstract

Twenty-nine bilateral breast carcinoma patients were analyzed retrospectively. The incidence of bilateral carcinoma of the breast among unilateral breast cancer patients was approximately 2.4%. Median age was 46 years at the time of first cancer diagnosis (range 26-69 years). The majority of the lesions were invasive ductal carcinoma (86%). Of 58 tumors, 10 were staged as Stage I (17%), 30 as Stage II (52%), 8 as Stage III (14%) and 10 as Stage IV (17%). Patients were treated with various combinations of surgery, radiation treatment and chemotherapy. Of 29 patients with bilateral breast cancer, 5 presented with simultaneous bilateral disease (17%), 7 (24%) with synchronous tumors whereas 17 (59%) developed asynchronous tumors. The mean interval between two cancers was 2.6 +/- 0.6 years. Overall survival was 4.8 +/- 0.7 years and overall 5-year actuarial survival was calculated to be 51%. Age, menopausal status and tumor size at the time of initial cancer correlated with the time interval between two cancers. Age, tumor size and nodal status at the time of initial cancer and the time interval between two cancers correlated with the overall survival.

Entities:  

Mesh:

Year:  1994        PMID: 7870220

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  2 in total

1.  Histo-biological comparative analysis of bilateral breast cancer.

Authors:  Bilal Baker; Basem Morcos; Faiez Daoud; Maher Sughayer; Maher Sughayyer; Hisham Shabani; Habeeb Salameh; Mahmoud Almasri
Journal:  Med Oncol       Date:  2013-09-24       Impact factor: 3.064

2.  Comparison of the histopathology and prognosis of bilateral versus unilateral multifocal multicentric breast cancers.

Authors:  Hüseyin Kadioğlu; Serdar Özbaş; Alper Akcan; Aykut Soyder; Lutfi Soylu; Savaş Koçak; N Zafer Cantürk; Mustafa Tükenmez; Mahmut Müslümanoğlu
Journal:  World J Surg Oncol       Date:  2014-08-20       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.